Merck gets CHMP backing for Keytruda-Padcev combo in bladder cancer
- Posted on September 21, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Merck gets CHMP backing for Keytruda-Padcev combo in bladder cancer
Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) has issued a positive opinion recommending approval of a combination of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in combination with Pfizer's PFE antibody-drug conjugate ("ADC"), Padcev (enfortumab vedotin-ejfv), for expanded use in a bladder cancer indication. The CHMP has now recommended the use of Keytruda...
